随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
Israel's defense minister says his country has attacked Iran and declares a state of emergency
。业内人士推荐91视频作为进阶阅读
Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.
The nuclear talks today are the third between the US and Iran since June 2025, when the US joined Israel’s war against Iran and bombed its nuclear and military sites. It effectively ended the US-Iran talks that were held in the weeks prior to the conflict aimed at reaching a nuclear peace agreement.